Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs
← catalyst calendarNCT07152379 · readout in 408 d
Sponsored by Cerus Corporation (industry) · CERS — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Screening
Enrollment
10estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-01 | estimated | When the study began enrolling |
| Primary completion | 2027-10-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-01-01 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Transfusion Reaction, Hemolytic
Interventions
- Device: 30-40 mL of INTERCEPT RBCs
- Device: ~30 mL of INTERCEPT RBCs plus plus 10 mL biotinylated INTERCEPT RBCs
Primary outcomes
what the primary-completion date above is the date OFAcute or delayed hemolytic transfusion reactions
measured 90 days
Clearance
measured 30 days
Permalink · CERS's whole pipeline · Catalyst calendar · Every registered study · What changed